Salarius Pharmaceuticals Inc
SLRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$404.53K
Close$
$2.30
173.8% upside
Current Fair Value
173.8% upsideUndervalued by 173.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $404,533.00 |
|---|---|
| Enterprise Value | $-4,886,623.00 |
| Earnings per Share | $-25.99 |
| Beta | 0.32 |
| Outstanding Shares | 481,587 |
Return
| Return on Equity | -334.41% |
|---|---|
| Return on Assets | -160.53% |
| Return on Invested Capital | -343.94% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.02 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -8.17 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 14, 2025
EPS Estimate
$-33.60
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.46%▲ 16.34% |
|---|---|
| Total Invested | $51,429▲ 2501.37% |
| Investors Holding | 9▲ 4.00% |
About Salarius Pharmaceuticals Inc
11 employees
CEO: David Arthur
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelera...